Evidence map›Paper›PMID 41957811›Full record

ArticleGenome medicine2026

Longitudinal cell-free DNA methylome and fragmentome profiles in health uncover signatures of cell type and demographic origin.

Mio Aerden, Tatjana Jatsenko, Kaat Leroy, Kobe De Ridder, Anna Nootens, Valentina Piatti, Koen Devriendt, Joris Robert Vermeesch, Huiwen Che, Bernard Thienpont

Abstract read
In one paragraph

Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mio AerdenLaboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven, Belgium.
Tatjana JatsenkoLaboratory for Cytogenetics and Genome Research, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Kaat LeroyLaboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven, Belgium.
Kobe De RidderLaboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven, Belgium.
Anna NootensLaboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven, Belgium.
Valentina PiattiLaboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven, Belgium.
Koen DevriendtCenter for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Joris Robert VermeeschCenter for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Huiwen Che *Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven, Belgium. huiwen.che@kuleuven.be.
Bernard Thienpont *Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven, Belgium. bernard.thienpont@kuleuven.be.

Funding

Fonds Wetenschappelijk Onderzoek S003422NKU Leuven C1- C14/22/125KU Leuven METH/21/06
6 · The paper itself

Abstract

backgroundCell-free DNA (cfDNA) is a powerful analyte for liquid biopsy applications. However, the composition and fragmentation of cfDNA in health remains incompletely characterized. Understanding this baseline variation is key to advancing cfDNA-based assay development.

methodsWe profiled 432 plasma cfDNA samples from 160 healthy individuals across two cohorts: a diurnal (n = 16) and a cross-sectional (n = 144) cohort, to evaluate circadian as well as demographic effects on estimated cfDNA concentration, cellular composition and fragmentomic characteristics. Targeted enzymatic methyl-sequencing was used to infer cell-type of origin and assess fragmentation patterns.

resultscfDNA concentration and fragment size exhibited circadian patterns, with morning samples showing 63% higher cfDNA concentrations (P = 1.8 × 10–5) and a 7% increase in mononucleosomal fragments (P = 2.3 × 10–4) compared to afternoon and evening samples. Cell-type-specific rhythms were observed in natural killer cells, monocytes, and hepatocytes, while other cell types remained relatively stable. In both the diurnal and cross-sectional cohort, hematopoietic lineages were the predominant sources of cfDNA. Cell-type contributions to cfDNA were more consistent within individuals than between individuals, reflecting relatively robust intraindividual profiles. Demographic variables, including sex, age and body mass index, influenced the contribution of specific blood cell types. By integrating cell-type-specific methylation, fragment size, and dinucleotide end motifs we uncovered distinct fragmentation signatures associated with individual cell type proportions. Granulocyte-derived cfDNA showed a consistent enrichment in mononucleosomal sizes (P < 1.0 × 10–16) and CC end motifs, while cfDNA from other cells exhibited distinct size and end-motif profiles. Additionally, hypomethylated DNA was associated with shorter fragment sizes and altered end-motif frequencies, emphasizing interactions between DNA methylation, nuclease activity and chromatin context in shaping cfDNA fragment characteristics.

conclusionsOur findings provide a comprehensive view on processes and cell types involved in cfDNA biogenesis in healthy individuals. They underscore that demographic variables and sampling time should be considered in cfDNA-based assay design, but also highlight opportunities to improve the representation of specific cell types in cfDNA, thus providing a foundation for optimizing cfDNA diagnostics by leveraging multiple axes of information.

Indexed as

Cell-Free Nucleic AcidsDNA MethylationEpigenomeAdultCircadian RhythmCross-Sectional StudiesFemaleHumansMaleMiddle AgedCell-Free Nucleic AcidsCell-free DNADeconvolutionEpigeneticsFragmentomicsLiquid biopsy

Identifiers

PMID41957811
PMCPMC13173710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.